MENU
+Compare
CANF
Stock ticker: ASE
AS OF
Aug 8 closing price
Price
$0.69
Change
-$0.00 (-0.00%)
Capitalization
12.74M

CANF Can-Fite BioPharma Ltd Forecast, Technical & Fundamental Analysis

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company... Show more

Industry: #Biotechnology
CANF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for CANF with price predictions
Aug 08, 2025

CANF's RSI Indicator stays in oversold zone for 10 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CANF advanced for three days, in of 214 cases, the price rose further within the following month. The odds of a continued upward trend are .

CANF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 24, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CANF as a result. In of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CANF turned negative on July 25, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CANF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CANF entered a downward trend on August 05, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.842) is normal, around the industry mean (18.712). P/E Ratio (0.000) is within average values for comparable stocks, (55.605). CANF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (3.011). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (7.391) is also within normal values, averaging (287.742).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CANF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CANF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
CANF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals for treatment of autoimmune diseases and cancers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
26 Ben Gurion Street
Phone
+972 39241114
Employees
5
Web
http://www.canfite.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BCTX0.710.03
+4.58%
Briacell Therapeutics Corp NEW
RKLB44.690.48
+1.09%
Rocket Lab Corporation
CAKE61.54-0.39
-0.63%
Cheesecake Factory
AMLX7.64-0.20
-2.55%
Amylyx Pharmaceuticals
TPIC0.32-0.38
-54.00%
TPI Composites

CANF and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CANF has been loosely correlated with ALDX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CANF jumps, then ALDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CANF
1D Price
Change %
CANF100%
+0.24%
ALDX - CANF
46%
Loosely correlated
+1.74%
OABI - CANF
31%
Poorly correlated
+4.79%
TPST - CANF
27%
Poorly correlated
+4.69%
ORMP - CANF
26%
Poorly correlated
+0.48%
IVF - CANF
25%
Poorly correlated
-0.55%
More